Genetic Testing

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat...

Ambry Genetics’ CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc....

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

SALT LAKE CITY, April 30, 2026 (GLOBE NEWSWIRE) -- The latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad...

Clairity Announces Update to NCCN Guidelines to Include AI Mammogram-Based Risk Tool to Identify Future Breast Cancer Risk in Women Missed by Traditional Methods

Major paradigm shift incorporates five-year risk assessment and identifies increased-risk women beginning at age 35 BOSTON, April 14, 2026 (GLOBE...

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

David Meeker Quote David Meeker Quote Dr. Shoemaker quote Dr. Shoemaker quote IMCIVREE packaging IMCIVREE packaging with vial IMCIVREE 3D...

Burnout and Chronic Stress Surge Across U.S. Workforce – Shifa Health Responds with New Precision Wellness Clinic on Its 23rd Anniversary

New integrative mental health program combines neuroscience, personalized assessments, and evidence-based psychiatric care to help individuals restore energy, resilience, and...

error: Content is protected !!